-- A wide-ranging review of the outcomes of cryoablation in 2,558 primary
prostate cancer patients showed efficacy of cryoablation in terms of
biochemical survival and low morbidity. The average age of the
patients, all part of the nationwide Cryo-On-Line Database (COLD)
Registry, was 70 years and 419 of the patients had more than five years
-- A 10-year, retrospective review of 78 patients at the University of
Texas M.D. Anderson Cancer Center demonstrated the effectiveness of
cryoablation for prostate cancer patients whose cancer returned after
being originally treated with radiation. After 10 years, more than 80
percent of the patients were disease free after cryoablation and the
investigators concluded that salvage cryoablation is curative in
approximately one-third of patients at 10-year follow up.
-- The first, multi-center study of focal, or partial gland, cryoablation
for 341 prostate cancer patients demonstrated that more than half of
the patients who were potent before the therapy were again potent after
six months, and more than 74 percent resumed potency within 36 months.
Focal cryoablation is designed to destroy the tumors in the prostate
while sparing the nerves to retain potency. These patients are also
part of the COLD Registry.
-- An 88-patient Cleveland Clinic study of the long term disease-free
survival rates (more than five years) of kidney cancer patients showed
that laparoscopic kidney cryoablation is an effective treatment in
select patients. The investigators determined that cancer-specific
survival of 95 percent is possible at five years and 88 percent is
possible at 10 years.
-- Six AUA-sponsored courses and workshops related to cryoablation
focused on prostate ultrasound, abdomi
|SOURCE Endocare, Inc.|
Copyright©2008 PR Newswire.
All rights reserved